Results 111 to 120 of about 176,622 (333)

Bevacizumab (Avastin) and Thermal Laser Combination Therapy for Peripapillary Choroidal Neovascular Membranes

open access: yesJournal of Ophthalmology, 2017
Objective. This is a retrospective interventional case series describing the results of 5 eyes from 5 patients with symptomatic peripapillary choroidal neovascularization (CNVM) receiving initial bevacizumab treatment followed by thermal laser and ...
Sean D. Adrean   +2 more
doaj   +1 more source

Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol. [PDF]

open access: yes, 2020
AimTo show the characteristics and outcomes of patients with neovascular age-related macular degeneration (nAMD) who had extended remission (ER) while on a pro re nata (PRN) treatment protocol.MethodsThis was a retrospective case-control study of a ...
Amador-Patarroyo, Manuel J   +6 more
core  

Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors [PDF]

open access: yes, 2015
Over the past few years, knowledge regarding the molecular pathology of sporadic pancreatic neuroendocrine tumors (PNETs) has increased substantially, and a number of targeted agents have been tested in clinical trials in this tumor type.
Ahn   +64 more
core   +1 more source

The Potential of Phytochemicals to Overcome Multidrug Resistance in Metastatic Melanoma

open access: yesChemistry &Biodiversity, EarlyView.
ABSTRACT Metastatic melanoma is the most lethal form of skin cancer, accounting for most skin cancer‐related deaths. Immunotherapies and targeted therapies have improved overall and progression‐free survival rates in metastatic melanoma patients. The effectiveness of these therapies decreases due to multidrug resistance (MDR).
Jacqueline Maphutha   +4 more
wiley   +1 more source

Widening use of dexamethasone implant for the treatment of macular edema [PDF]

open access: yes, 2017
Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis.
Avitabile T.   +9 more
core   +2 more sources

18 Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial [PDF]

open access: gold, 2020
Philipp Harter   +12 more
openalex   +1 more source

Bioorthogonal Chemistry in Biomolecule Quantification: A Review of Reactions and Strategies

open access: yesChemistry – A European Journal, EarlyView.
This review summarizes the application of catalyst‐free bioorthogonal reactions: Staudinger ligation, strain promoted azide alkyne cycloaddition, inverse electron‐demand Diels–Alder, and 2‐cyanobenzothiazole cysteine condensation in the semi‐quantitative and quantitative analysis of biomolecules.
Mingze Yang, Shiqi Wang
wiley   +1 more source

Systemic Therapy in Endometrial Cancer: Recent Advances. [PDF]

open access: yes, 2013
Endometrial cancer is a chemosensitive disease. Studies have established a clear benefit of chemotherapy in advanced stages and trials are ongoing to define its role in early stages as well.
Bhise, R   +5 more
core   +1 more source

Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors [PDF]

open access: yes, 2019
Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR), and both are widely used in combination with chemotherapy or as monotherapy to treat patients with RAS wild-type metastatic ...
Aderka, Dan   +6 more
core   +1 more source

Impact of Antihypertensive Treatment on Outcomes of Adjuvant Bevacizumab for Ovarian Cancer (IATRO), Results from a Nationwide Emulated Clinical Trial

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Antiangiogenic therapy with bevacizumab improves outcomes in ovarian cancer but induces hypertension, leading to major adverse cardiovascular events (MACE). While calcium channel blockers (CCBs) and angiotensin‐converting enzyme inhibitors (ACEi) are recommended for managing bevacizumab‐associated hypertension, their impacts on cancer progression and ...
Floriane Jochum   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy